Gilead pens $1.75bn deal with start-up Tango Therapeutics; deal expanded
Oncology start-up Tango Therapeutics Inc. signed its first major alliance, agreeing to discover and develop targeted immuno-oncology therapies with Gilead Sciences Inc.
- Specialty Pharmaceuticals
- Gene Therapy, Cell Therapy
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.